Answers are grounded in this paper and cite their sources.
The severe forms of intellectual disabilities (IDs) are associated with a wide range of treatment-resistant neuropsychiatric conditions including epilepsy, dementia (e.g. Alzheimer's disease in Down syndrome), attention deficit/hyperactivity, behavioural, sleep and movement disorders as well as self-injury, aggression anxiety, depression, and psychosis 1. The limited availability and poor quality of healthcare facilities for people with an ID often add to the inequality experienced by this vulnerable group in comparison to other people 2, 3. The crucial problem is that various behavioural disorders may reflect communication problems, sensory processing disorders, or undiagnosed somatic disorders rather than treatable psychiatric disorders. In addition, numerous psychotropic medicines are commonly prescribed in spite of the limited evidence of their benefits 4, 5. Consequently, this multidimensional uncertainty can easily lead to inappropriate medication accompanied by drug-induced side-effects. Intellectual disability is seldom curable and its prognosis depends on an etiology, but the prognosis can be considered good when using general wellbeing, quality of life and daily functioning of an individual as an endpoint. The burden neuropsychiatric disorders and other comorbidities place on an individual and, on the other hand, on society cannot be determined without careful clinical examination including etiological evaluations and definition of intelligence quotient and functional and communicative capabilities. All this speaks for the importance of individually tailored treatment and rehabilitation. Epilepsy is known to have a pervasive impact on the lives of individuals and their families affecting physical morbidity, leading to increased mortality and a heavier care-giving burden 6. The deleterious effects of epilepsy can in general be minimized by increasing diagnostic accuracy and by applying evidence-based treatment options, but for epilepsy patients with IDs such concrete aims are cumbersome to reach. First, an epilepsy diagnosis in relation to ID presents unique challenges due to complex etiology and commonly associated behaviour and communication disorders 6-8. Considering the wide differences known to exist in education and training for caregivers, it may be impossible for even an epilepsy expert to obtain a reliable anamnesis of a patient's seizure type and frequency upon which to base clinical decision making. Second, treatment of epilepsy in patients with IDs follows general consensus-based guidelines, which are based on clinical trials conducted mostly with patients without IDs. So, in spite of the huge reliance on pharmacotherapy in this patient group, there is only limited evidence of its benefits for the ID population. From both an organizational and clinical perspective, autistic spectrum disorders (ASD) belong to the most challenging comorbidities in IDs. About 35–75% of children diagnosed with ASD meet criteria for ID, and since 1960 more than 30 epidemiological studies have shown ASD prevalence to have increased from 4.4 per 10 000 during the period 1966–1991 to an average of 12.7 per 10 000 during the period 1992–2001 9. Currently, there is no consensus on whether there is a real increase in prevalence due to numerous confounding factors such as better diagnostics and changed definitions and terminology during the last decade. However, ASD is a lifelong condition without a clear singular etiology nor does it have a singular ‘cure’. The benefits of traditional antidepressants (selective serotonin reuptake inhibitors and tricyclic antidepressants) and neuroleptic agents (e.g. risperidone) in relieving autistic symptoms such as irritability, repetition and hyperactivity are limited and the usefulness of other less conventional treatment approaches are uncertain as concluded in recent Cochrane reviews 10-12. Furthermore, with a growing degree of cognitive and adaptive delays, the frequency of ASD symptoms is known to intensify, increasing the potential for diagnostic confusion. Treatment refractory, destructive behaviour problems are also common in IDs without ASD adding to the burden of caregivers. In general, the prevalence of severe behaviour problems has been estimated to occur among 10–20% of individuals with developmental disabilities 1. Aggressive and self-injurious behaviours place an individual or his or her caregivers at risk of physical harm. Physical aggression commonly includes kicking, pinching others and tearing, breaking or throwing objects, whereas typical self-injurious behaviour of persons with ID occurs as head banging, self-hitting, self-biting, self-pinching, self-scratching, hand mouthing, eye-poking, and hair-pulling. It is self-evident that such behaviours have a negative influence on the physical and emotional wellbeing of the staff taking care of these patients' basic needs on a daily basis. It is well known that medicines traditionally used to treat various neuropsychiatric disorders in patients with IDs may paradoxically worsen some of the psychiatric symptoms while relieving other symptoms. Both neuroleptics and SSRI-antidepressants may increase epileptic seizure frequency or even cause epileptic seizures as a class effect while ameliorating psychotic and depressive or other psychiatric symptoms respectively. Occasionally, a good response is achieved with a certain drug, but another prescription is needed to cover the adverse effects it has caused. Such polytherapy is not by any means advisable, but cannot always be avoided in a clinical realm. For example, in some cases, an antiepileptic medicine is needed to control epileptic seizures caused by clozapine, a neuroleptic that has turned out to be the only treatment option for an individual's otherwise treatment-resistant severe psychosis. Additionally, some antiepileptics such as levetirasetam may be associated with behavioural and neuropsychiatric adverse events or even sometimes worsen seizure control 13. Differentiation of drug-induced adverse events from ID-related symptoms may in certain cases be difficult (if not impossible). Individual seizure activity and severity of behavioural symptoms vary over time depending on etiologic and other organic or psychosocial factors. Thus, prior to initiating any new treatment, the basic fluctuations of the patient's symptoms should be evaluated as accurately as possible. This evaluation is usually largely based on anamnesis given by a caregiver, who may have known the patient for too limited a period of time to be able to give a reliable long-term anamnesis. In addition, a caregiver's education level influences the way earlier history is described to a clinician. The same may also well apply to a report on drug response and adverse reactions given by these first-line helpers. To avoid such misunderstandings leading to suboptimal pharmacotherapy with accompanying and possibly deleterious consequences on an individual's wellbeing, clinical follow-up and on-going education of caregivers are needed. In the fight against treatment-resistant symptoms, many families and caregivers tend to place high hopes on complementary and experimental therapies, some of which can result in high expenses without any factual knowledge of their benefit/risk profiles as recently reviewed in Cochrane analyses 7, 8, 10-12, 14. Considering the severity of neuropsychiatric symptoms in ID patients, the tendency to seek help from alternative treatment options is understandable when word of some positive experience spreads via patient organizations. Accordingly, a number of psychosocial and educational programmes are used for various neuropsychiatric disorders with highly variable outcomes 15. Therapies lacking empirical data can hardly be fully denied, but should only be applied under medical supervision and preferably as part of a research programme. With the plethora of numerous diagnostic and therapeutic complexities, chances for misdiagnosis and unnecessary medication in patients with an ID can be considered more a rule than an exception, all of which without doubt has multidimensional consequences. Inappropriate health management increases the risk of side-effects caused by possible false diagnosis and hence unnecessary medications. Consequently, the poor health conditions of persons with ID leads to increased sick leaves and burnout among care staff. Thus, establishment of an ID-oriented clinical unit providing multidisciplinary team services is considered essential to prevent a cascade of undesired events caused by insufficient healthcare of people with IDs. Close collaboration on a routine basis between neurologists, psychiatrists, other medical experts as well as neuropsychologists, psychologists, social workers, physical, music and other therapists should form a basis for the comprehensive healthcare of ID patients in an ID-oriented unit. Necessary diagnostic evaluations and various consultations considered case-by-case would be coordinated by a physician (preferably with a subspecialty in ID medicine). Access to both polyclinic and in-ward medical services should be provided upon individual need, that is, whenever a patient's general condition worsens or there are some otherwise unsolvable conflicts between family members and caregivers. The responsibilities of an ID-oriented clinical unit would include etiologic and diagnostic evaluations, utilization of evidence-based therapies, research on commonly used as well as new complementary therapies, multidisciplinary intervention of treatment-resistant neuropsychiatric disorders, and education of family members and caregivers. The suggested centralized health management of ID patients can be expected to provide several benefits. First, once etiology is known, individual prognosis can be estimated and direct medical services planned accordingly. Known etiology also reduces a parent's feelings of guilt and shame related to having a child with ID. Second, enhancement of diagnostic accuracy decreases the risk of inappropriate medications, unnecessary polypharmacy, resulting in better overall wellbeing of ID patients. Third, general knowledge of IDs and associated comorbidities would improve, thus leading to more effective care of this vulnerable patient group with special needs. In light of literature and our long-term clinical experience, the need for the special ID units seems evident.
No takes yet. Share an insight, caveat, or question.
Bjelogrlic‐Laakso et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: